{
    "title": "Rapid Telomere Extension",
    "inventor_name": "Helen Blau (et al.)",
    "publication_year": null,
    "device_name": "Nucleoside-modified mRNA encoding telomerase",
    "goal": "Rapidly extend telomeres to prevent or treat hypertension and other age-related conditions",
    "problem_addressed": "Telomere shortening that contributes to hypertension, heart failure, immunosenescence and vascular dementia",
    "concept_summary": "A transient, non-integrating mRNA drug containing modified nucleosides (pseudouridine, 5-methylcytidine) encodes telomerase. Delivered intravenously (e.g., via autologous exosomes), it expresses telomerase for a few days, extending telomeres in six days by an amount equivalent to 15 years of normal aging. The brief exposure preserves normal anti-cancer telomere-shortening mechanisms and avoids genome integration.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Modified nucleoside mRNA to reduce immunogenicity",
        "Transient expression of telomerase",
        "Exosome-mediated intravenous delivery"
    ],
    "scientific_domains": [
        "Molecular Biology",
        "Genetics",
        "Gene Therapy",
        "Regenerative Medicine"
    ],
    "mechanisms_of_action": [
        "Telomerase reverse transcriptase expression",
        "Telomere elongation in endothelial and progenitor cells",
        "Prevention of cellular senescence"
    ],
    "materials": [
        "mRNA",
        "Pseudouridine",
        "5-methylcytidine (m5C)",
        "Exosomes (autologous)",
        "Cap analogs and poly(A) tails"
    ],
    "energy_sources": [],
    "inputs": [
        "Modified telomerase mRNA",
        "Intravenous delivery vehicle (exosomes or RNA lipid particles)"
    ],
    "outputs": [
        "Extended telomeres",
        "Reduced endothelin-1 production",
        "Lower blood pressure"
    ],
    "claimed_performance": "Extends telomeres in six days by the amount lost over 15 years of normal human aging; prevents hypertension in short-telomere mouse model.",
    "experimental_evidence": "In the short-telomere mTERC-null mouse model of hypertension, intravenous delivery of the mRNA drug extended endothelial telomeres and prevented endothelial senescence, reducing hypertension-related phenotypes.",
    "replication_status": "Demonstrated in mouse model; human studies not yet performed.",
    "keywords": [
        "telomere extension",
        "modified mRNA",
        "telomerase",
        "exosome delivery",
        "hypertension",
        "aging therapy"
    ],
    "related_technologies": [
        "INCOGNITO mRNA platform",
        "RNA vaccine technology",
        "Gene therapy vectors"
    ],
    "controversy_level": "low",
    "confidence_score": 0.8,
    "practicability_score": 0.6,
    "fringe_score": 0.2,
    "evidence_strength": 0.5,
    "risk_score": 0.3,
    "trl_estimate": 4,
    "source_urls": [
        "http://grantome.com/grant/NIH/R21-AG044815-02",
        "https://patents.google.com/patent/US2014242154",
        "https://patents.google.com/patent/WO2014130909",
        "http://www.cellscript.com/"
    ],
    "organizations": [
        "Stanford University",
        "CELLSCRIPT"
    ],
    "applications": [
        "Treatment of hypertension",
        "Therapy for age-related cardiovascular disease",
        "Potential use in immunosenescence and vascular dementia"
    ],
    "limitations": [
        "Transient expression requires precise dosing",
        "Delivery vehicle optimization still needed",
        "Long-term safety (tumorigenesis) not yet established"
    ],
    "open_questions": [
        "What is the durability of telomere extension after treatment cessation?",
        "Can the approach be scaled to humans without adverse immune responses?",
        "Will repeated dosing be required for chronic conditions?"
    ],
    "red_flags": [
        "Potential for tumor formation if telomerase is over-expressed",
        "Regulatory hurdles for gene-therapy-type RNA drugs"
    ],
    "evidence_quotes": [
        "Our mRNA drug extends telomeres in six days by approximately the amount by which telomeres shorten over 15 years of normal human aging on average, and our drug is transient, being turned over within a few days.",
        "We will test autologous exosomes as vehicles for i.v. delivery of our drug.",
        "In the short-telomere mTERC-null mouse model of hypertension, telomere extension prevents endothelial cell senescence.",
        "The drug does not integrate with the genome, is non-immunogenic as it comprises the same modified nucleosides recently discovered to comprise mature mammalian mRNA."
    ]
}